Screener
Chemed CHE Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Chemed in its filing.
Tagged under the XBRL concept us-gaap:StockOptionPlanExpense.
The source filing: Chemed’s 10-Q, filed April 28, 2026.
- Filed
- Apr 28, 2026, 9:00 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000019584-26-000012
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Adjustments to reconcile net income to net cash provided | ||
| by operating activities: | ||
| Depreciation and amortization | 16,873 | 16,017 |
| Stock option expense | 9,249 | 9,091 |
| Benefit for deferred income taxes | (4,737) | (14,174) |
| Noncash long-term incentive compensation | 1,386 | 2,420 |
| Amortization of debt issuance costs | 80 | 80 |
| Changes in operating assets and liabilities: |
Item 1. Financial Statements
FAQ
- What is Chemed's stock-based comp?
- Chemed (CHE) reported stock-based comp of $9.25M in Q1 2026.
- How has Chemed's stock-based comp changed year-over-year?
- Chemed's stock-based comp increased by 1.7% year-over-year, from $9.09M to $9.25M.
- What is the long-term trend for Chemed's stock-based comp?
- Over 4 years (2021 to 2025), Chemed's stock-based comp has grown at a 5.3% compound annual growth rate (CAGR), from $31.42M to $38.68M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Chemed's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude